EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC

Leonie Hartl iD, Joris J T H Roelofs iD, Frederike Dijk iD, Maarten F Bijlsma iD, JanWillem Duitman iD, C Arnold Spek iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24021537 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Leonie Hartl und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam UMC Location University of Amsterdam…. Hauptthemen laut MEDLINE: CCAAT-Enhancer-Binding Proteins, Gene Expression Regulation, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amsterdam UMC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a poor clinical prognosis and unsatisfactory treatment options. We previously found that the transcription factor CCAAT/Enhancer-Binding Protein Delta (C/EBPδ) is lowly expressed in PDAC compared to healthy pancreas duct cells, and that patient survival and lymph node involvement in PDAC is correlated with the expression of C/EBPδ in primary tumor cells. C/EBPδ shares a homologous DNA-binding sequence with other C/EBP-proteins, leading to the presumption that other C/EBP-family members might act redundantly and compensate for the loss of C/EBPδ. This implies that patient stratification could be improved when expression levels of multiple C/EBP-family members are considered simultaneously. In this study, we assessed whether the quantification of C/EBPβ or C/EBPγ in addition to that of C/EBPδ might improve the prediction of patient survival and lymph node involvement using a cohort of 68 resectable PDAC patients. Using Kaplan–Meier analyses of patient groups with different C/EBP-expression levels, we found that both C/EBPβ and C/EBPγ can partially compensate for low C/EBPδ and improve patient survival. Further, we uncovered C/EBPβ as a novel predictor of a decreased likelihood of lymph node involvement in PDAC, and found that C/EBPβ and C/EBPδ can compensate for the lack of each other in order to reduce the risk of lymph node involvement. C/EBPγ, on the other hand, appears to promote lymph node involvement in the absence of C/EBPδ. Altogether, our results show that the redundancy of C/EBP-family members might have a profound influence on clinical prognoses and that the expression of both C/EPBβ and C/EBPγ should be taken into account when dichotomizing patients according to C/EBPδ expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CCAAT-Enhancer-Binding ProteinsGene Expression RegulationPancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansCCAAT-Enhancer-Binding Protein-betaCCAAT-Enhancer-Binding Protein-deltaLymph NodesLymphatic MetastasisPrognosis

Stichwörter der Autor:innen

C/EBPCEBPBCEBPDCEBPGPDAClymph node involvementredundancy

Substanzen

CCAAT-Enhancer-Binding Protein-betaCCAAT-Enhancer-Binding Protein-deltaCCAAT-Enhancer-Binding ProteinsCEBPD protein, humanCCAAT-enhancer-binding protein-gammaCEBPB protein, human

Autor:innen und Institutionen

  • Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Cancer Biology and Immunology, 1081 HV Amsterdam, The Netherlands.
  • Department of Pathology, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Department of Pulmonary Medicine, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Amsterdam Infection & Immunity, Inflammatory Diseases, 1105 AZ Amsterdam, The Netherlands.

ORCID-Profile: Leonie Hartl, Joris J T H Roelofs, Frederike Dijk, Maarten F Bijlsma, JanWillem Duitman, C Arnold Spek

Förderung

  • Amsterdam UMC

Zitieren

APA

Hartl, L., Roelofs, J. J. T. H., Dijk, F., Bijlsma, M. F., Duitman, J., & Spek, C. A. (2023). C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021537

Vancouver

Hartl L, Roelofs JJTH, Dijk F, Bijlsma MF, Duitman J, Spek CA. C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24021537

BibTeX
@article{Hartl2023,
  author = {Hartl, Leonie and Roelofs, Joris J T H and Dijk, Frederike and Bijlsma, Maarten F and Duitman, JanWillem and Spek, C Arnold},
  title = {C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24021537}
}
Kostenlos starten →